Filing Details

Accession Number:
0001387131-21-004685
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-20 17:06:35
Reporting Period:
2021-04-16
Accepted Time:
2021-04-20 17:06:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1601830 Recursion Pharmaceuticals Inc. RXRX () C0
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1419351 Pjsc Holding Global Diversified Mamoura P. O. Box 45005
Abu Dhabi C0 UAE
No No Yes No
1704268 Mubadala Investment Co Pjsc P.o. Box 45005
Abu Dhabi C0 00000
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2021-04-20 3,578,653 $0.00 3,578,653 No 4 C Indirect See Explanation of Responses
Class A Common Stock Acquisiton 2021-04-20 2,738,824 $0.00 6,317,477 No 4 C Indirect See Explanation of Responses
Class A Common Stock Acquisiton 2021-04-20 745,392 $0.00 7,062,869 No 4 C Indirect See Explanation of Responses
Class A Common Stock Acquisiton 2021-04-16 2,777,777 $18.00 2,777,777 No 4 P Indirect See Explanation of Responses
Class A Common Stock Acquisiton 2021-04-20 5,963,140 $0.00 8,740,917 No 4 C Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Explanation of Responses
No 4 C Indirect See Explanation of Responses
No 4 C Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
No 4 C Indirect See Explanation of Responses
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Series B Convertible Preferred Stock Disposition 2021-04-20 3,578,653 $0.00 3,578,653 $0.00
Class A Common Stock Series C Convertible Preferred Stock Disposition 2021-04-20 2,307,475 $0.00 2,738,824 $0.00
Class A Common Stock Series D Convertible Preferred Stock Disposition 2021-04-20 745,392 $0.00 745,392 $0.00
Class A Common Stock Series D Convertible Preferred Stock Disposition 2021-04-20 5,963,140 $0.00 5,963,140 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
  2. Consists of (i) 2,777,777 shares held of record by Fifteenth Investment Company LLC and (ii) 5,963,140 shares held of record by Thirty Fifth Investment Company LLC. Both Fifteenth Investment Company LLC and Thirty Fifth Investment Company LLC are wholly owned subsidiaries of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.
  3. On April 16, 2021, Fifteenth Investment Company LLC acquired 2,777,777 Class A Shares at a price of $18 per share in connection with Recursion Pharmaceutical, Inc.'s (the "Issuer") initial public offering.
  4. Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
  5. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.
  6. The shares of Series B Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.
  7. The shares of Series C Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1.1869 basis automatically upon the closing of the initial public offering of the Issuer.
  8. The shares of Series D Convertible Preferred Stock were automatically converted into Class A Shares on a 1-for-1 basis automatically upon the closing of the initial public offering of the Issuer.